How should I interpret this hormone panel for a premenopausal, non‑pregnant woman drawn in the luteal phase, and what further evaluation is recommended for the elevated DHEA‑Sulfate (DHEA‑S)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Hormone Panel Interpretation and Elevated DHEA-S Evaluation

The elevated DHEA-S (343 µg/dL; reference 57.3-279.2) in this premenopausal woman with luteal-phase progesterone (2.2 ng/mL) requires further evaluation to exclude adrenal pathology, though values below 600 µg/dL typically indicate benign hyperandrogenism such as PCOS rather than adrenal neoplasm.

Key Findings Analysis

Testosterone Levels

  • Total testosterone: 41 ng/dL (normal: 4-50)
  • Free testosterone: 2.4 pg/mL (normal: 0.0-4.2)

Both testosterone values are within normal limits, which argues against severe hyperandrogenic states or androgen-secreting tumors.

Progesterone Assessment

The progesterone level of 2.2 ng/mL is elevated for luteal phase (reference 1.8-23.9), confirming ovulation occurred. This is appropriate timing for hormone evaluation and suggests the patient has ovulatory cycles, making PCOS less likely as the primary diagnosis 1.

DHEA-S Elevation

The DHEA-S of 343 µg/dL represents mild elevation above the upper limit of normal (279.2 µg/dL). This is clinically significant but well below the critical threshold of 600 µg/dL (16,000 nmol/L) that would mandate urgent abdominal imaging for adrenal adenoma 2.

Clinical Significance and Next Steps

Risk Stratification

According to established guidelines, DHEA-S levels above 600 µg/dL indicate possible androgen-secreting adrenal cortical adenoma and require rapid abdominal CT or MRI 2. Your patient's level does not meet this threshold.

Differential Diagnosis for Mild DHEA-S Elevation

The combination of:

  • Mildly elevated DHEA-S
  • Normal testosterone levels
  • Confirmed ovulation (luteal progesterone 2.2 ng/mL)

Suggests several possibilities:

  1. Mild adrenal hyperandrogenism without clinical significance - Research shows 50% of anovulatory women and 34% of oligomenorrheic women have elevated DHEA-S, with 77% being non-hirsute 3, 4. Even in ovulatory women, 19% show elevated DHEA-S 4.

  2. Subclinical PCOS variant - Though ovulation is documented, some women with PCOS maintain ovulatory cycles while exhibiting isolated androgen elevation 3.

  3. Non-classic congenital adrenal hyperplasia (NCCAH) - Particularly 3β-hydroxysteroid dehydrogenase deficiency, which can present with isolated DHEA-S elevation 3.

Recommended Evaluation Algorithm

Immediate Assessment (Required)

  1. Clinical evaluation for hyperandrogenism:

    • Hirsutism (Ferriman-Gallwey score if present)
    • Acne severity
    • Androgenic alopecia
    • Acanthosis nigricans
    • Central obesity/metabolic features
  2. Menstrual history:

    • Cycle regularity (oligomenorrhea suggests PCOS)
    • Fertility concerns
    • Family history of diabetes or PCOS

Laboratory Follow-up Based on Clinical Findings

If symptomatic hyperandrogenism present (hirsutism, acne, alopecia):

  • 17-hydroxyprogesterone (17-OHP) - Early morning, follicular phase to screen for NCCAH 1
  • Androstenedione - May be elevated when testosterone is normal 2
  • SHBG - To calculate free androgen index if metabolic syndrome suspected 2
  • Fasting glucose and lipid panel - PCOS metabolic screening 1
  • Pelvic ultrasound - Assess for polycystic ovarian morphology 1

If asymptomatic (no hirsutism, regular cycles, no metabolic features):

  • Repeat DHEA-S in 3-6 months to confirm persistence 5
  • No immediate additional testing required - Research demonstrates DHEA-S measurements are relatively consistent over time in individuals 5, so a single mildly elevated value in an asymptomatic patient may represent benign variation

Advanced Testing (Only if Initial Workup Abnormal)

If 17-OHP elevated (>200 ng/dL):

  • ACTH stimulation test to confirm NCCAH 2, 3

If clinical or ultrasound features suggest PCOS despite ovulatory cycles:

  • Consider metabolic evaluation even with normal androgens 1

Important Caveats

Timing Considerations

  • Testosterone should be measured early morning, days 4-10 of menstrual cycle for standardized interpretation 1, 6
  • DHEA-S can be measured at any time as it lacks diurnal variation 6
  • Your luteal-phase timing is appropriate for progesterone but suboptimal for testosterone interpretation

Assay Limitations

Current immunoassays for androgens lack sensitivity and specificity at low female ranges 6, 7. If clinical suspicion remains high despite normal testosterone, consider sending samples to a specialty laboratory using liquid chromatography-tandem mass spectrometry (LC-MS/MS) 1, 6.

Age-Related Changes

DHEA-S naturally declines with age 6. Reference ranges may not account for sexual dysfunction or other clinical correlates, so interpret in full clinical context.

When to Reassure vs. Investigate Further

Reassurance appropriate if:

  • No hirsutism, acne, or androgenic alopecia
  • Regular menstrual cycles (confirmed by progesterone)
  • No metabolic syndrome features
  • No fertility concerns
  • DHEA-S <400 µg/dL

Further investigation required if:

  • Any clinical hyperandrogenism present
  • Menstrual irregularity develops
  • Fertility issues emerge
  • DHEA-S rises toward 600 µg/dL on repeat testing
  • Family history of NCCAH or high-risk ethnicity (Ashkenazi Jewish, Hispanic, Slavic) 1

Urgent imaging (CT/MRI abdomen) mandatory if:

  • DHEA-S ≥600 µg/dL 2
  • Testosterone >2× upper limit of normal 2
  • Rapid virilization or Cushing's features 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.